POZ - Treatment News : Isentress Wins Approval in European Union
Subscribe to:
POZ magazine E-newsletters
POZ Personals Sign In / Join
Username:
Password:

Back to home » Treatment News » December 2007

Web Exclusives

Looking Back, Moving Forward: Reflections on USCA

NAPWA Testifies Before Congress

Renewing the Denver Principles

» More

Most Talked About

A 'Functional' Cure for HIV? (17)

Just Found Out? A POZ.com Guide for HIV Rookies (14)

Only Took Me 23 Years... (blog) (14)

The State of AIDS in Puerto Rico (13)

Politicians Urge Bush for Final Repeal of HIV Travel Ban (11)

TGI Friday’s Fined for Firing HIV-Positive Employee (8)

What's That Mean?
(just double-click it!)

NEW! If you don't understand one of the words in this article, just double-click it. A window will open with a definition from CancerWEB's On-line Medical Dictionary. If the double-click feature doesn't work in your browser, you can enter the word below:


Most Popular Lessons

The HIV Life Cycle

Herpes Simplex Virus

Human Papilloma Virus (HPV)

Shingles

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

10 Years Ago In POZ


More Treatment News

Click here for more news

Have news about HIV? Send press releases, news tips and other announcements to news@poz.com.


emailrssprint

December 21, 2007

Isentress Wins Approval in European Union

The HIV integrase inhibitor Isentress (raltegravir) was approved in the European Union today for use in combination with other antiretrovirals for treatment-experienced patients who have detectable viral loads despite ongoing antiretroviral therapy.

The approval of Isentress, developed and manufactured by Merck & Co., allows for access to the drug in the 27 European Union countries, as well as Norway and Iceland. It was approved earlier this year in the United States, Canada and Mexico.

Isentress is a promising HIV drug for treatment-experienced patients with drug-resistant virus because it works differently than other available antiretrovirals. After HIV’s genetic material is deposited inside a cell, its RNA must be converted (reverse transcribed) into DNA. A viral enzyme called integrase then helps to hide HIV’s DNA inside the cell’s DNA. Once this happens, the cell can begin producing genetic material for new viruses. Integrase inhibitors, such as Isentress, are designed to block the activity of the integrase enzyme and to prevent HIV DNA from meshing with healthy cell DNA.


Scroll down to comment on this story.

emailrssprint


Name: (2-50 characters)
Email: (will not show)
City: (optional)

Comment (500 characters left):

(Note: The POZ team review all comments before they are posted. Please do not include either ":" or "@" in your comment.)

| Posting Rules

Previous Comments:

  comments 1 - 4 (of 4 total)    

Chris, San Francisco, 2007-12-29 23:02:56
Hey Ken from Lauderhil, or anyone else taking Isentress, what's your experience with side effects on this med? Any lipo side effects or others you've experience so far?

peter abbott, san francisco, 2007-12-28 02:26:16
News about approval in the EU is interesting for me because I have coverage in Austria and have found in the past that Austria does its own approval process and sadly if they choose to "save" money, they don't even consider the approval process. So thus it is not approved. Expensive meds are thus kept out of the country or on self-pay.

Ken, Lauderhill FL, 2007-12-27 17:39:20
I started on Isentress the beginning of Oct 07 and in 30days of being on the med my viral load when undecided for the first time in 16yrs

Richard Dow, Nyack, NY 10960, 2007-12-26 13:42:31
Is Isentress approved for use in USA? In process? Or how soon might it be approved? Thanks R.

comments 1 - 4 (of 4 total)    


[Go to top]

Get Started
Get Answers
What to do if you've just been diagnosed
How to find a support system
Things you should know before starting treatment
How to handle side effects and other concerns
How to tell someone you have HIV/AIDS

Talk to Us
Weekly Poll
Question: Have you ever been tested for TB?
Yes
No

Monthly Poll
Question: Do you think the new American president will effectively address HIV/AIDS issues during his first 100 days?
Yes
No
I don't know

Surveys
Tell us about your travel experiences.

Tell us about your pets.

more surveys  
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertise/contact us | site map]
© 2008 Smart + Strong. All Rights Reserved. Terms of use and Your privacy